https://medi-paper.com/wp-content/uploads/2023/05/MPR-FOS-2023019-HKMA-HKSID-Launch-4-MAR-scaled.jpg
1366
2560
Jeffrey Martin
https://medi-paper.com/wp-content/uploads/2020/02/MediPR-MediPaper-Medical-Communications-Ltd-Healthcare-Writers-Medical-Writers-Medical-Writer-Agency-Hong-Kong-Medical-Writing-Services-Solutions-Quote-醫學寫作-香港-醫學作家香港-medical-PR-public-relations-1030x374.png
Jeffrey Martin2023-05-17 12:25:412023-05-31 12:39:03Achieving the Best Outcomes under COVID-19 EndemicityNon-Sponsored Content
CARDIOVASCULAR DISEASE
有關疫苗的虛假信息
Medical writer: Dr Siddharth Sridhar | Last updated: 11 January 2021 | In: COVID-19, SARS-CoV2, Pneumonia, Infectious Disease, Vaccines
Article Keywords
Moderna, mRNA-1273, Sinovac, Pfizer, WARS, tozinameran, AZ, SARS-CoV-2, China, AZD1222, 2019-nCoV, BioNTech, corona virus, BNT162b2, COVID-19, ChAdOx1-nCoV-19, CoronaVac, Fosun Pharma, pneumonia
我最近在YouTube頻道上看到這條在2020年12月17日發佈的視頻(https://www.youtube.com/watch?v=RYCwCOGCu9A&feature=youtu.be),聲稱說明有關COVID-19疫苗的功效和風險。該視頻的內容非常不準確且具有誤導性。 令我震驚的是,該視頻已吸引了超過三十萬觀看者,其中有幾位評論者表示同意偽科學。
視頻裡的講者提出了多項主張,我對此進行了事實核查:
1.他聲稱SARS-CoV-2的棘突蛋白可通過與人類細胞上的EGFR結合而直接導致肺纖維化(永久組織變硬)。這就是他認為COVID-19引起肺炎的方式。
事實核查:這是不正確的。大多數COVID-19患者沒有發展成永久性肺纖維化,只有少數患者由於嚴重的肺損傷才會。肺纖維化是任何嚴重肺炎的潛在後果,而不僅僅是COVID-19。纖維化是組織受到損傷後形成的一種疤痕,它不受病毒尖刺控制,而是源自人體修復的過程。具體而言,沒有證據表明尖刺有“甲基轉移酶”的作用。他引用的“ NSP16”是功能完全不同的基因產物。
2.他指出製藥公司“不敢”製作滅活病毒疫苗,因為它們仍然會引起疾病。
事實核查:幾間公司和大學正在研究SARS-CoV-2滅活病毒疫苗。而疫苗還未可應用的原因,僅僅是因為“弱化”病毒和驗證弱化效果的過程需要花費很多時間,因此無法迅速推出。 我相信在未來幾年內試用滅活病毒疫苗。
3.他特別指出,mRNA疫苗不能抵禦COVID-19,因為它們會刺激生產一種稱為IgG的抗體。他提出了怪異的說法,就是IgG不能抵禦COVID-19,因為它存在於血液而不是肺中。
事實核查:完全是錯誤的。當該視頻發佈到YouTube時,輝瑞和Moderna研發的疫苗試驗結果已經發佈,這無疑證明了疫苗的有效預防率達九成以上。這意味著,與未接種疫苗的人士相比,接種疫苗的人士患上COVID-19的可能性降低了百份之九十以上。IgG可以預防COVID-19,因為在我們需要預防COVID-19的肺部深處的肺泡上皮液中也發現了IgG。另外,他認為產生IgA的吸入性疫苗是一種有吸引力的選擇也算是正確,並且多個機構(包括香港大學)都在積極研發這類疫苗,但毫無疑問,目前已獲批的疫苗可有效抵抗COVID-19。他要麼不知道,要麼就是故意無視mRNA疫苗的第三期隨機對照試驗的結果。
4.最危險的是他接著提出的另一種說法,即因為mRNA能進入腎臟和肝臟而其疫苗可引致多器官纖維化。
事實核查:這是絕對沒有任何理論或事實依據。實際上,注射mRNA疫苗後會在我們的身體中表達少量尖刺蛋白,及後便會迅速降解,而所產生的尖刺蛋白便足以激發強大的免疫反應,僅此而已。而且,不論是mRNA或是尖刺蛋白均未發現積聚在器官內。另外,這也揭穿他於上述第1點有關尖刺蛋白直接導致纖維化的假說。
5.最後,他介紹了許多可能對抗COVID-19有用的營養補品
事實核查:零證據。 他提到的“對接”是一種基於計算機的靈活模擬方法,用於查看某些分子是否可以與SARS-CoV-2蛋白產生相互作用。除非有可靠的臨床前和臨床試驗證據來支持,否則會產生很多關於“對接”的發現而不能得到證實。
這是有關疫苗的一種最危險和有害的虛假信息,似乎是由受過某些科學訓練的人寫下的偽科學。對於不熟悉課題的觀眾來說,很難區分事實和捏造。對我們每個人來說,應避免於自己家庭的Whatsapp群組和Facebook時間線上發佈這種虛假信息,是十分重要的。
堅持核實事實,祝周末愉快!
YOU MAY ALSO LIKE
https://medi-paper.com/wp-content/uploads/2023/05/MPR-FOS-2023019-HKMA-HKSID-Launch-4-MAR-scaled.jpg
1366
2560
Jeffrey Martin
https://medi-paper.com/wp-content/uploads/2020/02/MediPR-MediPaper-Medical-Communications-Ltd-Healthcare-Writers-Medical-Writers-Medical-Writer-Agency-Hong-Kong-Medical-Writing-Services-Solutions-Quote-醫學寫作-香港-醫學作家香港-medical-PR-public-relations-1030x374.png
Jeffrey Martin2023-05-17 12:25:412023-05-31 12:39:03Achieving the Best Outcomes under COVID-19 Endemicity
https://medi-paper.com/wp-content/uploads/2023/01/INACTIVATED-AND-mRNA-COVID-19-VACCINES-IN-PATIENTS-WITH-AUTOIMMUNE-RHEUMATIC-DISEASES-–-A-CITY-OF-TWO-TALES.jpg
1024
1918
Connie TANG
https://medi-paper.com/wp-content/uploads/2020/02/MediPR-MediPaper-Medical-Communications-Ltd-Healthcare-Writers-Medical-Writers-Medical-Writer-Agency-Hong-Kong-Medical-Writing-Services-Solutions-Quote-醫學寫作-香港-醫學作家香港-medical-PR-public-relations-1030x374.png
Connie TANG2023-01-30 10:47:542023-02-02 16:50:53Inactivated and mRNA COVID-19 vaccines in patients with autoimmune rheumatic diseases – A city of two tales
https://medi-paper.com/wp-content/uploads/2023/01/Late-but-sinister-post-COVID-19-conditions_new-onset-rheumatic-diseases.jpg
1024
1918
Christy Leung
https://medi-paper.com/wp-content/uploads/2020/02/MediPR-MediPaper-Medical-Communications-Ltd-Healthcare-Writers-Medical-Writers-Medical-Writer-Agency-Hong-Kong-Medical-Writing-Services-Solutions-Quote-醫學寫作-香港-醫學作家香港-medical-PR-public-relations-1030x374.png
Christy Leung2023-01-16 12:18:572023-03-08 12:48:36Late but sinister post-COVID-19 conditions: new-onset rheumatic diseases
https://medi-paper.com/wp-content/uploads/2023/01/COVID-19-Infection-and-Subfertility-A-Subtle-and-Debatable-Complication.jpg
1024
1918
Christy Leung
https://medi-paper.com/wp-content/uploads/2020/02/MediPR-MediPaper-Medical-Communications-Ltd-Healthcare-Writers-Medical-Writers-Medical-Writer-Agency-Hong-Kong-Medical-Writing-Services-Solutions-Quote-醫學寫作-香港-醫學作家香港-medical-PR-public-relations-1030x374.png
Christy Leung2023-01-16 11:32:342023-01-19 18:28:49COVID-19 Infection and Subfertility: A Subtle and Debatable ComplicationDisclaimer
This article is not medical advice. Patients should seek personal assessment by a licenced specialist. Physicians are recommended to read the full publication(s) as cited in the article before making medical decisions. This article does not supersede nor replace the published article(s).
© Copyright 2021 MediPaper Medical Communications Ltd. – 有關疫苗的虛假信息
YOU MAY ALSO LIKE
© Copyright 2021 MediPaper Medical Communications Ltd. – 有關疫苗的虛假信息
![Medical News Asia | Powered by ['mediPr]](https://medi-paper.com/wp-content/uploads/2020/02/MediPR-MediPaper-Medical-Communications-Ltd-Healthcare-Writers-Medical-Writers-Medical-Writer-Agency-Hong-Kong-Medical-Writing-Services-Solutions-Quote-醫學寫作-香港-醫學作家香港-medical-PR-public-relations-1030x374.png)




Achieving the Best Outcomes under COVID-19 Endemicity
Inactivated and mRNA COVID-19 vaccines in patients with autoimmune rheumatic diseases – A city of two tales
Late but sinister post-COVID-19 conditions: new-onset rheumatic diseases
COVID-19 Infection and Subfertility: A Subtle and Debatable Complication
COVID-19 VACCINE BOOSTER STRATEGY: STRIVING FOR THE BEST
Protection is Never Premature: Maternal COVID-19 Infection is Associated with Adverse Perinatal Outcomes
Updates on COVID-19 Vaccine Booster in Omicron Era
Should your child receive covid-19 vaccination? Risk-benefit analyses in infants, children, and adolescents
At the Heart of the Discussion: COVID-19 Cardiovascular Complications in Pregnant Women
Covid-19 vaccination safety and effectiveness for pregnant and lactating women
HKMA CME Live Lecture: Dr Ho SO – Vaccination Safety and Effectiveness in Immunocompromised Patients
Vaccination versus Active Infection: A Comparison of the Cardiovascular Risks
Common Respiratory Viruses and Their Associated Cardiovascular Risks
Strategy for COVID-19 vaccination: Disease control, elimination or eradication?
SARS-CoV-2 evolution in the COVID-19 era: Three years and counting
UK statistics suggest COVID-19 variant types as “long COVID” progression predictors
COVID-19 Antiviral Treatment and Booster Vaccine Effectiveness
Feasibility of Implementing Population-Wide Opt-Out HIV Testing Scheme
An Overview of the South African COVID-19 Subvariant Outbreak
COVID-19 Vaccinations in Adolescents and Children
Monkeypox Virus: How Likely is a Local Outbreak?
Local Updates on COVID-19 Prevention and Treatment
Tolerability of COVID-19 vaccines in patients with cancer
More Severe Outcomes in COVID-19 Patients with Cancer
COVID-19 vaccination safety and effectiveness for pregnant and lactating women
Gut Microbiome: Predictor for COVID-19 Vaccine Response and Safety (CZ02 and BNT162b2)
US Study Suggests A Lesser-known COVID-19 Complication: Diabetes Mellitus
Vaccination Strategies and Management Against Omicron Outbreak
UK study: Infected adolescents are at higher risk of long COVID symptoms
Antiviral Molnupiravir Associated with Reduced Risk of Hospitalisation or Death in COVID-19 Patients
Anti-TNF Therapy Correlated with Better Outcomes in IBD Patients with COVID-19
The use of COVID-19 vaccines in children and adolescents
HPV immunisation in UK lowers the incidence of cervical cancer and CIN3
Combination therapy with a novel agent, albuvirtide, in hospitalised AIDS patients
BioNTech COVID-19 vaccine for ages 5 to 11 years – To jab or not to jab?
Gender-related differences in safety after switching to BIC/TAF/FTC
Effect of HIV infection on growth and bone density in peripubertal children under antiretroviral therapy
Safety and Immunogenicity of the BNT162b2 mRNA Covid-19 Vaccine in Patients after Allogeneic HCT or CD19-based CAR-T therapy
Efficacy and safety of HIV fusion inhibitor albuvirtide in treatment experienced patients from phase 3 TALENT study
COVID-19 impacting regular patient care for cardiovascular diseases
SARS-CoV-2 infection in children and an increased risk of thrombotic microangiopathy
Evidence of SARS-CoV2 in heart cells
Triple combination effective for hospital- and ventilator-acquired pneumonia
Risk of thrombosis with SARS-CoV-2 infection
No difference in kidney transplantation outcomes for HIV-positive recipients regardless of donor HIV status
Residual risk of hepatocellular carcinoma in older Hepatitis C patients even after viral clearance
Potential protective effects of the influenza vaccine on cardiovascular outcomes in high-risk populations
Updated human papillomavirus vaccination and testing recommendations from the American Cancer Society
Interim results of a Phase 2b/3 trial investigating a long-acting injectable of cabotegravir for pre-exposure prophylaxis of HIV
Comparison of the metabolic changes from the TANGO trial: a post-hoc analysis
Carboplatin plus paclitaxel to be the new standard of care for anal cancer
更新: Covid-19患者的臨床特徵
Updated: Clinical characteristics of patients with COVID-19
開始? 結束?
COVID-19 in Hong Kong: the end of the beginning?
How do people get COVID-19 in Hong Kong
在本港,人們如何感染Covid-19?
2019-nCoV – Summary of the situation in HK as of Feb 6, 2020
2019-nCoV在本港的概況(截至2020年2月6日)
新型冠狀病毒(2019-nCoV)的傳染性有多高?
How infectious is novel coronavirus (2019-nCoV)
2019-nCoV: how stable are coronaviruses in the environment?
2019-nCoV: 冠狀病毒在環境中的穩定性
Who gets severe novel coronavirus (2019-nCoV) infection?
誰受到 2019-nCoV嚴重感染?